ANKHD1 (Ankyrin Repeat and KH Domain Containing 1) is a multidomain protein implicated in diverse cellular processes, including transcriptional regulation, signal transduction, and cell cycle control. Structurally, it contains ankyrin repeats, which mediate protein-protein interactions, and a K homology (KH) domain, often associated with RNA/DNA binding. Research suggests ANKHD1 plays roles in cancer progression, particularly in leukemia, breast cancer, and hepatocellular carcinoma, where it may modulate oncogenic pathways like Hippo or JAK-STAT signaling.
ANKHD1 antibodies are essential tools for studying its expression, localization, and molecular interactions. These antibodies are typically produced in hosts like rabbits or mice using immunogenic peptides or recombinant protein fragments. Validation often includes Western blotting, immunofluorescence, and immunohistochemistry (IHC) to confirm specificity, sometimes supported by knockout cell line controls.
In cancer research, ANKHD1 antibodies help assess its overexpression in tumors, correlate levels with clinical outcomes, or explore its interaction with partners like STAT3 or YAP1. Emerging studies also link ANKHD1 to non-cancer processes, such as immune regulation and cardiovascular functions. However, its full mechanistic repertoire remains under investigation. Commercially available antibodies vary in clonality (monoclonal/polyclonal) and applications, requiring careful selection based on experimental needs. Overall, ANKHD1 antibodies are pivotal in elucidating its dual roles as a potential oncotherapeutic target or biomarker.